Article: DNAPrint's $35M Stock Sale Will Finance German Buy-In.

West Coast Editor

With a commitment in hand to sell up to $35 million of its own common stock, DNAPrint genomics Inc. agreed to spend $25 million for a 51.8 percent stake in the Leverkusen, Germany-based pharmaceutical firm Biofrontera AG.

"It's a different approach," said Richard Gabriel, president and CEO of Sarasota, Fla.-based DNAPrint, adding that the funding route "certainly is dilutive, but at the same time there aren't many options out there for biotech companies that are in need of cash."

The company's stock (OTC BB:DNAP) closed Wednesday at 2 cents, up 46.7 percent from the previous closing of .007 cents.

Under the terms, ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!